International Patent Application for its Dynorphin Peptides Vancouver, British Columbia--(Newsfile Corp. - July 7, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed an International PCT application on July 1, 2021, entitled "Peptides and uses thereof", application number PCT/AU2021/050707 with the aim of seeking protection for certain peptides and their use in pain management.
There is a need for the development of new drugs that are effective in pain management, while also having fewer side-effects, in particular dependence and tolerance, and greater in vivo stability. There is also a need for a larger selection of pain management drugs to choose from.
This invention is predicated, at least in part, on the discovery of peptidic dynorphin analogues that have selective activity in relation to opioid receptors and have improved stability in vivo, allowing longer-lasting pain management.
The International patent application is to protect the dynorphin peptide research that appears to show the most potential for further development as an alternative therapeutic agent to the current opioids, such as morphine, in the management of pain.
PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "In the current times of opioid crisis, it is very necessary to have a natural mechanism for analgesia as an alternate for a painkiller to opioids such as morphine, which can have significant side effects including constipation, sedation, respiratory depression, dependence and tolerance. We are very excited and pleased that our program has identified peptides that can potentially address the much-needed alternative for an opioid for opioids such as morphine."
Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com